AbbVie Raises 2026 Neuroscience Revenue Guidance to $12.7 Billion

3-line summary

• AbbVie now expects its neuroscience portfolio to generate approximately $12.7 billion in revenue during 2026, raising guidance by another $100 million after a strong first half, up from $10.8 billion generated last year, according to a Yahoo Finance report.
• Second-quarter neuroscience revenue climbed 20.3% year over year to $3.23 billion, with migraine drugs Ubrelvy and Qulipta rising a combined 22.6%; Q2 immunology revenue reached $8.79 billion, driven by Skyrizi and Rinvoq.
• AbbVie is also developing bretisilocin, a psychedelics-based candidate for major depressive disorder acquired from Gilgamesh Pharmaceuticals, which remains in clinical trials.

This summary is our own processing of the source article; see the source link below for full context.